Development of Liquisolid Compacts: An Approach for Dissolution Enhancement of Poorly Aqueous Soluble Drugs

Solubility plays a key role to achieve desired concentration of drug in systemic circulation and show its pharmacological action. An approach of liquisolid technique, developed by Spireas, was employed for the dissolution enhancement of poorly aqueous soluble drugs. Initially, liquid medication (liquid drug or drug solution or suspension in hydrophilic liquid vehicle) is transformed to free-flowing, non-sticky, compressible powder by the addition of suitable carrier material and coating materials for the development of liquisolid compacts. The postulated mechanism for enhanced solubility was improved wettability of drug and enhanced surface area of molecularly dispersed drug in the liquid environment. Pre- and post-the compression tests were performed for the developed liquisolid compacts to obtain optimized formulation. For the optimized compacts, FTIR and DSC studies were performed for determining drug-excipient compatibility; SEM and PXRD studies were performed to study the solid-state characterization. Furthermore, accelerated stability studies were performed for optimized liquisolid compacts for 6 months according to ICH guidelines and the results were compared with freshly prepared formulations. In conclusion, liquisolid compact formulation was proved to be safe, economic and alternative approach to formulate solid oral dosage forms of poorly aqueous soluble drugs.

Read the full paper on Liquisolid Compacts here

Following excipients are mentioned in the research paper besides other: Avicel PH 101, Avicel PH 102, Neusilin, Fujicalin, Aerosil 200, Tween 20

Kasturi, Madhavi. “Development of Liquisolid Compacts: An Approach for Dissolution Enhancement of Poorly Aqueous Soluble Drugs”. Drug Formulation Design [Working Title], edited by Rahul Shukla, IntechOpen, 2022.
10.5772/intechopen.108706.